Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study

• Main Authors: Maria Di Pietrantonio (Author), Lucia Brescini (Author), Jennifer Candi (Author), Morroni Gianluca (Author), Francesco Pallotta (Author), Sara Mazzanti (Author), Paolo Mantini (Author), Bianca Candelaresi (Author), Silvia Olivieri (Author), Francesco Ginevri (Author), Giulia Cesaretti (Author), Sefora Castelletti (Author), Emanuele Cocci (Author), Rosaria G. Polo (Author), Elisabetta Cerutti (Author), Oriana Simonetti (Author), Oscar Cirioni (Author), Marcello Tavio (Author), Andrea Giacometti (Author), Francesco Barchiesi (Author)
• Format: Book
• Published: MDPI AG, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...